Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NAOV 
NanoVibronix Inc (NAOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NAOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -91.86% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.02M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) - | Beta 1.76 | 52 Weeks Range 0.67 - 9.47 | Updated Date 06/29/2025 |
52 Weeks Range 0.67 - 9.47 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -210.82% | Operating Margin (TTM) -180.68% |
Management Effectiveness
Return on Assets (TTM) -12.08% | Return on Equity (TTM) -28.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6327332 | Price to Sales(TTM) 1.14 |
Enterprise Value 6327332 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA 0.43 | Shares Outstanding 2584840 | Shares Floating 2584473 |
Shares Outstanding 2584840 | Shares Floating 2584473 | ||
Percent Insiders 3.22 | Percent Institutions 2.31 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NanoVibronix Inc
Company Overview
History and Background
NanoVibronix, Inc. was founded in 2003. It focuses on developing noninvasive therapeutic ultrasound devices. Key milestones include FDA approvals for its pain and wound healing devices and strategic partnerships for market expansion.
Core Business Areas
- PainShieldu00ae: A disposable patch delivering low-intensity therapeutic ultrasound for pain relief. Targets musculoskeletal pain, soft tissue injuries, and post-operative pain. Competes with opioid painkillers and other pain management devices.
- UroShieldu00ae: An ultrasound-based device designed to prevent catheter-associated urinary tract infections (CAUTIs). Competes with antibiotic treatments and other CAUTI prevention methods.
Leadership and Structure
Brian Murphy serves as the CEO. The company has a board of directors and operates with functional departments, including research & development, sales & marketing, and operations.
Top Products and Market Share
Key Offerings
- PainShieldu00ae: A single-use disposable patch that delivers low-intensity therapeutic ultrasound. Market share is small but growing within the non-opioid pain management sector. Estimated revenue is difficult to pinpoint. Competitors: BioWave, Zynex, electrical stimulation devices.
- UroShieldu00ae: An ultrasound system to prevent CAUTIs in catheterized patients. The company has been focused on market entry and distribution. Estimated revenue is difficult to pinpoint. Competitors: Bard, Coloplast, Convatec, antimicrobial catheters.
Market Dynamics
Industry Overview
The medical device industry is competitive and subject to regulatory scrutiny. Demand for non-invasive and drug-free therapies is increasing.
Positioning
NanoVibronix positions itself as an innovator in non-invasive therapeutic ultrasound, offering alternative solutions to pain management and infection prevention.
Total Addressable Market (TAM)
The TAM for pain management and CAUTI prevention is substantial, estimated in the billions of dollars globally. NanoVibronix is targeting niche segments within this large market.
Upturn SWOT Analysis
Strengths
- Proprietary ultrasound technology
- Non-invasive treatment options
- Potential for reduced reliance on drugs
- Focus on specific medical needs
Weaknesses
- Limited financial resources
- Small market share
- Dependence on regulatory approvals
- Relatively small sales and marketing team
Opportunities
- Expanding distribution networks
- Securing partnerships with healthcare providers
- Developing new applications for ultrasound technology
- Growing awareness of non-invasive therapies
Threats
- Competition from established medical device companies
- Regulatory changes
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- Zynex (ZYXI)
- BioWave
- Becton, Dickinson and Company (BDX)
Competitive Landscape
NanoVibronix faces competition from larger, more established companies with greater resources. Its competitive advantage lies in its proprietary ultrasound technology and focus on niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, influenced by regulatory approvals, market adoption, and financing.
Future Projections: Future growth depends on successful commercialization of products and expansion into new markets. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding distribution partnerships and pursuing regulatory approvals in new territories.
Summary
NanoVibronix is a small company with innovative technology targeting niche markets. Its limited resources and dependence on regulatory approvals create challenges, but it has significant growth potential if it can successfully commercialize its products and expand its market reach. The company needs to carefully manage its cash flow and monitor competitive threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Investor Relations, Press Releases, Industry Reports, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice, and readers should consult with a qualified financial advisor before making investment decisions. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoVibronix Inc
Exchange NASDAQ | Headquaters Tyler, TX, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Dr. Doron Robert Besser M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 31 | Website https://www.nanovibronix.com |
Full time employees 31 | Website https://www.nanovibronix.com | ||
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.